HHS forges strategic partnerships with two global companies to develop new antibiotics
ASPR announced two strategic partnerships with The Medicines Co. and Roche to develop new products to combat the threat of multi-drug resistant bacterial infections. Under the contract, BARDA will manage and share the cost of developing a portfolio of products with each company.
-
Contaminated Water in Flint
Flint, Michigan is facing a serious public health crisis, with high levels of lead in its water supply. HHS is committed to supporting the residents and health agencies in Flint and across Michigan.
From the HHS Blog:
Making Progress on Combating Antibiotic Resistance
Most of modern medicine is possible because antibiotics gave us the power to fight common infections. Unfortunately, this tool’s power has gradually diminished . To find a solution, the CARB Task Force has been working to implement the National Action Plan for over a year now.
Federal prize competition seeks innovative ideas to combat antimicrobial resistance
Contestants will vie for $20m in prizes to develop new innovative laboratory diagostic tools that detect and distinguish antibiotic resistant bacteria. The prize is sponsored by two HHS components, NIH and ASPR, in support of the National Action Plan for Combating Antibiotic Resistant Bacteria.
-
HHS accelerates development of mRNA-based Zika vaccine
ASPR’s BARDA awards over $8m to speed development of a Zika vaccine using the messenger RNA technology. This type of vaccine uses mRNA containing the genetic sequence of the Zika virus to generate an immune response in people. Producing vaccine from this type of technology is rapid compared to traditional vaccine technologies.
|
|